Related Experiment Videos
Intralesional alpha interferon. Cost-effective therapy for vulvar vestibulitis syndrome
S C Marinoff1, M L Turner, R P Hirsch
1George Washington University School of Medicine and Health Sciences, Washington, D.C.
The Journal of Reproductive Medicine
|January 1, 1993
Summary
Intralesional alpha interferon injections are a cost-effective first-line treatment for vulvar vestibulitis syndrome (VVS), offering significant savings compared to surgery alone. This approach improves patient outcomes and reduces overall healthcare costs for VVS management.
Area of Science:
- Gynecology
- Dermatology
- Health Economics
Background:
- Vulvar vestibulitis syndrome (VVS) is a chronic condition causing introital dyspareunia.
- Treatment options include intralesional alpha interferon and surgery, but cost-effectiveness data is limited.
Purpose of the Study:
- To compare the cost-effectiveness of intralesional recombinant alpha interferon injections followed by surgery versus a hypothetical model of surgery alone for VVS.
Main Methods:
- Prospective study of 55 patients with VVS (HPV- and non-HPV-associated).
- Interventions: intralesional alpha interferon injections, with surgery for nonresponders/responders.
- Comparison: hypothetical model of surgery alone.
- Outcome measures: subjective improvement (dyspareunia, sexual function) and objective changes (erythema, tenderness).
- Statistical analysis: overall improvement probability, costs, and cost per patient.
Main Results:
- 49% of patients achieved substantial or partial improvement with alpha interferon.
- Of non-responders, 19 underwent surgery, achieving 84% substantial and 11% partial improvement.
- The alpha interferon group (including subsequent surgery) demonstrated significant cost savings compared to surgery alone.
Conclusions:
- Intralesional alpha interferon is a cost-effective first-choice treatment for VVS.
- This strategy offers significant cost savings while achieving comparable or improved patient outcomes.